Located in Beijing, we focus on pioneering clinical research and advancing the biopharmaceutical industry. Our commitment to innovation has led us to achieve significant milestones, including our recent qualification for conducting clinical applications of lutetium [(177) lutetium]. This achievement marks an important stride in the realm of nuclear medicine in China.

A New Era for Nuclear Medicine

As a cancer research hospital, GoBroad is at the forefront of integrating advanced medical technologies into patient care. China has implemented stringent regulations governing the clinical application of nuclear medicine, making our recent progress particularly noteworthy. By obtaining approval for the use of lutetium-177, we are facilitating groundbreaking treatments for patients with gastrointestinal and pancreatic neuroendocrine tumors, conditions that have historically been challenging to manage.

We understand the importance of thorough research and development in providing solutions to severe diseases. Our dedicated team is engaged in a promising clinical trial investigating the effectiveness of peptide receptor-mediated radionuclide therapy (PRRT) using lutetium-177. Led by the esteemed Professor Lu Ming from Peking University Cancer Hospital and GoBroad, this trial embodies our commitment to advancing cancer treatment options while utilizing cutting-edge nuclear medicine techniques.

Enhancing Patient Outcomes Through Innovation

At GoBroad, we recognize that hope lies in innovative treatment approaches. The PRRT trial has shown significant promise, with early results suggesting improved disease control compared to existing therapies. Professor Lu Ming has expressed confidence in the therapy’s potential, emphasizing the clear advantages it presents for patients facing neuroendocrine tumors. Our cancer research hospital is dedicated to transforming these advancements into real-world benefits for our patients.

The growing vitality of nuclear medicine in China is indicative of our nation’s investment in healthcare innovation. As a strategic emerging industry, nuclear medicine not only supports the treatment of cancer but also enhances the overall landscape of medical technology. At GoBroad, we pride ourselves on being part of this dynamic field, continuing to lead the charge in clinical research and patient care.

Looking Ahead: The Future of Cancer Care

As we look toward the future, our goals at GoBroad remain steadfast: to deliver unparalleled cancer treatment and foster advancements in medical research. Achieving qualifications for lutetium-177 clinical applications is just the beginning of our journey in redefining the standards of oncological care. We strive to remain at the cutting edge of developments in nuclear medicine, ensuring that we bring hope and healing to our patients.

Conclusion

In conclusion, GoBroad stands as a pillar in the cancer research hospital landscape, committed to innovating patient care through rigorous research and clinical excellence. Our dedication to advancing nuclear medicine reflects our unwavering resolve to improve the lives of those fighting cancer, and we are excited about the future possibilities that lie ahead.